Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

CGI-Clinics Data-driven cancer genome interpretation for personalised cancer treatment

Coordinator
Fundacio Institut De Recerca Biomedica (irb Barcelona), Spain
Runs
1 November 2022 to 31 October 2027
Status
Running
EU funding
€9.6m
Total cost
€9.6m
Partners
22 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101057509

What the project is doing

In the project's own words, from its summary on CORDIS.

CGI-Clinics aims at improving personalised medicine in oncology by optimizing genomic data interpretation (after sequencing and before advising on compatible targeted therapies). Interpretation is a bottleneck for the full deployment and broad accessibility of Next Generation Sequencing (NGS) in cancer management. The project tackles the 3 main hurdles in the interpretation of cancer mutations: it is not systematic, it deals with a majority of variants of unknown significance and it fails to empower patients.

The interpretation of tumor genomic data relies on the work of experts reviewing scattered databases and resources, in a time-consuming process that may lead to suboptimal clinical decisions. CGI-clinics will systematize the interpretation process by integrating relevant public and private databases hospitals in a one-stop shop tool, with the possibility to organize virtual molecular tumor boards co-facilitated by reference hospitals.

Project will have three phases: a setup (assess needs), validation (pilot with the 9 clinical partners) and replication (30 hospitals across EU). It will enable democratization of genomic data interpretation (independent of their size, resources and profiling technology) and provide health economics validation. Relying on a systematic automatic learning platform, GCI-Clinics will increase the share of interpretable variants in tumors (from the current 9-12% to at least 50%), and features that constitute biomarkers of drug response.

The interpretation process is complex for most cancer patients, alienating them from knowledge of their illness. CGI-Clinics will build eduCGI, an app to help them understand the information gained through interpretation of their tumors, facilitating informed discussions with clinicians and sharing their data for research. Ultimately, the project is built to inform policy-makers on cancer management and empower patients.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Recerca Biomedica (irb Barcelona)BarcelonaSpainCoordinator
European Cancer Patient CoalitionBruxelles / BrusselBelgiumParticipant
Klinikum Der Universitaet Zu KoelnKoelnGermanyParticipant
Universitaetsklinikum AachenAachenGermanyParticipant
Ethniko Kentro Erevnas Kai Technologikis AnaptyxisThermi ThessalonikiGreeceParticipant
Alira Health SLBarcelonaSpainParticipant
Althaia Xarxa Assistencial Universitaria De Manresa Fundacio PrivadaManresaSpainParticipant
Consorcio Para La Explotacion Del Centro Nacional De Analisis GenomicoBarcelonaSpainParticipant
Fundacio Centre De Regulacio GenomicaBarcelonaSpainParticipant
Fundacio Institut D'investigacio Biomedica De Girona Doctor Josep TruetaGironaSpainParticipant
Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio)BarcelonaSpainParticipant
Fundacion Cientifica De La Asociación Espanola Contra El CancerMadridSpainParticipant
Fundacion Publica Andaluza Progreso Y Salud M.p.SevillaSpainThird party
Institut Catala D'oncologiaHospitalet de LlobregatSpainThird party
Servicio Andaluz De SaludSevillaSpainParticipant
Alira HealthParisFranceThird party
Centre De Lutte Contre Le Cancer Leon BerardLyonFranceParticipant
Institut Gustave RoussyVillejuifFranceParticipant
Alira Health S.r.lMilanoItalyThird party
European Association for Cancer ResearchNottinghamUnited KingdomAssociatedpartner
The University of ManchesterManchesterUnited KingdomAssociatedpartner
Alira Health Boston LLCFraminghamUnited StatesThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI